In Vivo Therapeutic Articles & Analysis: Older
9 news found
We continue making progress in realizing our mission to empower patients with access to one-time permanent cures made possible by next-generation in vivo therapeutics, and democratizing disease detection with next-generation molecular ...
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present preclinical data highlighting its cytoTIL15™ program during a poster session at the upcoming AACR Annual Meeting 2022. ...
Sun joins Mammoth from Halozyme Therapeutics Inc., a public biotechnology company focused on the subcutaneous delivery of biologics and small molecule therapeutics, where she served as Senior Vice President and CFO, leading the company’s finance, accounting, information technology, site operations and the Hylenex® commercial business. ...
Enables expansion of novel CRISPR platform, including proprietary ultra-small Cas14 and Cas? CRISPR systems for in vivo gene-editing therapeutics Makes key appointment of biotech veteran Gary Loeb as general counsel Mammoth Biosciences, the biotech company leveraging the diversity of life to build the next generation of CRISPR products to cure and detect ...
Sustained release of MF was demonstrated in vitro and in vivo for 2 MF matrices of distinct release durations and an in vitro–in vivo correlation was established. Therapeutic levels of MF in local tissues were measured throughout the intended dosing durations. ...
Data presented at AAIC demonstrates oral lead product candidate OLX-07010 reduces tau self-association and insoluble tau aggregates Oligomerix to begin clinical testing of OLX-07010 in 2Q22 Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced ...
Hanover, Germany, July 13, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced the results of extensive in vitro and in vivo studies demonstrating the therapeutic potential of H19 gene therapy to combat ...
As Redbiotec enters the field of gene therapy with engineered bacteria as means to improve in vivo delivery of therapeutics, we greatly appreciate the research experience and regulatory insights brought by Dr. ...
” Presenting companies in the NSF track include: ADMdx – Diagnostics Platform (Neuroimaging) Biodesy – Drug Discovery Platform (In Silico) Carmot – Drug Discovery Platform (Chemotype Evolution) CertiChem – Assay Platform (Estrogenic Activity in vitro, & in vivo) Jade Therapeutics - Drug Delivery Platform (Ophthalmology, ...